Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center
Mediterranean Journal of Hematology and Infectious Diseases · 30.04.2026 · 18 (1) · e2026044
DOI: 10.4084/mjhid.2026.044 ↗Kurz gefasst
Leserbrief in der Zeitschrift Mediterranean Journal of Hematology and Infectious Diseases, online erschienen am 30.04.2026. Verfasst von Muruvvet Seda Aydin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Ankara Bilkent City Hospital, Ankara, Turkiye. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Ruxolitinib has been associated with an increased risk of viral infections and tuberculosis reactivation in patients with Philadelphia chromosome-negative myeloproliferative neoplasm. However, data regarding screening practices and prophylactic approaches in routine clinical care remain limited.
Objective
To describe latent tuberculosis screening, antiviral prophylaxis practices, and infectious outcomes in ruxolitinib-treated patients with myeloproliferative neoplasm at a single center.
Methods
Thirty patients with Philadelphia chromosome-negative myeloproliferative neoplasm treated with ruxolitinib were included in this retrospective single-center study.
Results
The median duration of ruxolitinib therapy was 20.1 months. Latent tuberculosis screening was performed in nearly all patients, and isoniazid prophylaxis was administered to five individuals according to screening results. No tuberculosis reactivation occurred during follow-up. Antiviral prophylaxis was administered to 56.6% of patients. One patient developed herpes zoster during treatment, and two experienced recurrent oral herpes. Exploratory analyses did not identify statistically significant clinical factors associated with recurrent oral herpes or antiviral prophylaxis initiation.
Conclusion
This study provides a descriptive real-world account of infectious outcomes and institutional screening and management practices in ruxolitinib-treated patients with Philadelphia chromosome-negative myeloproliferative neoplasm. Larger prospective studies are required to further clarify optimal screening and prophylactic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Ankara Bilkent City Hospital, Ankara, Turkiye.
- Department of Infectious Diseases, Ankara Bilkent City Hospital, Ankara, Turkiye.
Zitieren
APA
Aydin, M. S., Korkmaz, G., Pamukcuoglu, M., Guner, H. R., Ceran, F., Dagdas, S., & Ozet, G. (2026). Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center. Mediterranean Journal of Hematology and Infectious Diseases, 18(1), e2026044. https://doi.org/10.4084/mjhid.2026.044
Vancouver
Aydin MS, Korkmaz G, Pamukcuoglu M, Guner HR, Ceran F, Dagdas S, et al. Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center. Mediterranean Journal of Hematology and Infectious Diseases. 2026;18(1):e2026044. doi:10.4084/mjhid.2026.044
BibTeX
@article{Aydin2026,
author = {Aydin, Muruvvet Seda and Korkmaz, Gülten and Pamukcuoglu, Merve and Guner, Hatice Rahmet and Ceran, Funda and Dagdas, Simten and Ozet, Gulsum},
title = {Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center},
journal = {Mediterranean Journal of Hematology and Infectious Diseases},
year = {2026},
volume = {18},
number = {1},
pages = {e2026044},
doi = {10.4084/mjhid.2026.044}
}
EUVIMED